Paper46337
The essential role of glucagon in the pathogenesis of diabetes mellitus.
Unger RH and 1 other. Lancet, 1975. Cited by 563 papers, by iCite.
Cite this record
ConductScience Library. The essential role of glucagon in the pathogenesis of diabetes mellitus. Papers, record 46337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/46337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus | Major topic |
| Glucagon | Major topic |
| Alanine | |
| Animals | |
| Blood Glucose | |
| Diabetes Mellitus, Experimental | |
| Dogs | |
| Glucose | |
| Growth Hormone-Releasing Hormone | |
| Humans | |
| Hyperglycemia | |
| Insulin | |
| Insulin Secretion | |
| Islets of Langerhans | |
| Liver | |
| Pancreatectomy |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02337660 | Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia | Background |
Source ClinicalTrials.gov
Cited by208
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 563 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42458466 | Glucagon receptor blockade protects spermatogenesis by enhancing PFKFB3-mediated lactate production in Sertoli cells. | J Transl Med | 2026 | https://conductscience.org/library/papers/42458466 | PubMed |
| 41818159 | Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion. | Am J Physiol Endocrinol Metab | 2026 | https://conductscience.org/library/papers/41818159 | PubMed |
| 41774508 | Glucagon promotes net hepatic glycogen repletion following meal ingestion. | JCI Insight | 2026 | https://conductscience.org/library/papers/41774508 | PubMed |
| 41502124 | Prolonged Somatostatin Receptor 2 Antagonism Enhances Glucagon Response to Hypoglycemia in Male Diabetic Rats. | Endocrinology | 2026 | https://conductscience.org/library/papers/41502124 | PubMed |
| 41206016 | Glucagon, the Alpha Cell, and Potential Targets for Diabetes Treatment. | Endocrinology | 2025 | https://conductscience.org/library/papers/41206016 | PubMed |
| 40924110 | Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations. | Diabetologia | 2025 | https://conductscience.org/library/papers/40924110 | PubMed |
| 40854221 | Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis. | Diabetes | 2025 | https://conductscience.org/library/papers/40854221 | PubMed |
| 40822953 | Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40822953 | PubMed |
| 40771639 | REVISITING GLUCAGON ACTION IN DIABETES: IS IT ALL BAD? | Trans Am Clin Climatol Assoc | 2025 | https://conductscience.org/library/papers/40771639 | PubMed |
| 40725617 | A Historical and Epistemological Review of Type 1 Diabetes Mellitus. | J Clin Med | 2025 | https://conductscience.org/library/papers/40725617 | PubMed |
| 40606916 | Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus. | World J Hepatol | 2025 | https://conductscience.org/library/papers/40606916 | PubMed |
| 40271226 | The Glucagon Receptor Is Expressed in the Frontal Cortex and Impaired Signaling Associates With Cognitive Decline. | J Endocr Soc | 2025 | https://conductscience.org/library/papers/40271226 | PubMed |
| 40105688 | Target Discovery to Diabetes Therapy-TXNIP From Bench to Bedside With NIDDK. | Endocrinology | 2025 | https://conductscience.org/library/papers/40105688 | PubMed |
| 40080261 | RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management. | J Cardiovasc Transl Res | 2025 | https://conductscience.org/library/papers/40080261 | PubMed |
| 40055529 | Islet hormones at the intersection of glucose and amino acid metabolism. | Nat Rev Endocrinol | 2025 | https://conductscience.org/library/papers/40055529 | PubMed |
| 39925097 | A new C-peptide minimal model to assess β-cell responsiveness to glucagon in individuals with and without type 2 diabetes. | Am J Physiol Endocrinol Metab | 2025 | https://conductscience.org/library/papers/39925097 | PubMed |
| 39776190 | Lessons from a model: early glucagon dysfunction in type 2 diabetes. | Pflugers Arch | 2025 | https://conductscience.org/library/papers/39776190 | PubMed |
| 39742505 | G6PC2 controls glucagon secretion by defining the set point for glucose in pancreatic α cells. | Sci Transl Med | 2025 | https://conductscience.org/library/papers/39742505 | PubMed |
| 39653064 | Enhanced quantification of α-cell suppression by hyperglycemia using a high-sensitivity glucagon assay. | Am J Physiol Endocrinol Metab | 2025 | https://conductscience.org/library/papers/39653064 | PubMed |
| 39601887 | Hyperglucagonemia and glucagon hypersecretion in early type 2 diabetes result from multifaceted dysregulation of pancreatic mouse α-cells. | Pflugers Arch | 2025 | https://conductscience.org/library/papers/39601887 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/46337
GET https://conductscience.org/api/papers/v1/46337/cited_by?page=2